FibroGen, Inc. (NASDAQ:FGEN) Director James A. Schoeneck Acquires 250,000 Shares

FibroGen, Inc. (NASDAQ:FGEN) Director James A. Schoeneck acquired 250,000 shares of the firm’s stock in a transaction on Thursday, March 20th. The shares were acquired at an average price of $0.35 per share, with a total value of $87,500.00. Following the completion of the transaction, the director now directly owns 323,722 shares in the company, valued at approximately $113,302.70. This trade represents a 339.11 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

FibroGen Trading Up 12.1 %

FibroGen stock traded up $0.04 during mid-day trading on Monday, hitting $0.35. 600,885 shares of the company’s stock were exchanged, compared to its average volume of 2,325,364. FibroGen, Inc. has a 1-year low of $0.18 and a 1-year high of $2.80. The stock has a 50 day moving average of $0.49 and a two-hundred day moving average of $0.43. The stock has a market cap of $35.62 million, a P/E ratio of -0.29 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $3.14 million for the quarter, compared to the consensus estimate of $24.91 million. As a group, research analysts predict that FibroGen, Inc. will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Mackenzie Financial Corp lifted its position in shares of FibroGen by 416.6% in the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock worth $290,000 after acquiring an additional 441,083 shares during the period. Velan Capital Investment Management LP acquired a new stake in FibroGen during the fourth quarter worth $42,000. Squarepoint Ops LLC bought a new stake in FibroGen in the 4th quarter valued at $205,000. Two Sigma Investments LP raised its stake in shares of FibroGen by 19.6% in the 4th quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 98,888 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in shares of FibroGen by 18.3% during the 4th quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after acquiring an additional 135,600 shares during the period. Institutional investors and hedge funds own 72.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on FGEN shares. StockNews.com started coverage on shares of FibroGen in a research report on Saturday. They issued a “hold” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of FibroGen in a research note on Tuesday, March 18th.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.